Explores the complexity of cancer, challenges in research translation, and the applications of tissue engineering for cancer models and drug screening.
Explores the selection and rationale of preclinical animal models in drug development, emphasizing the 10 to 15-year path to a marketed small-molecule drug.
Explores small molecule drugs for infectious diseases, covering global mortality rates, viral and bacterial injuries, antiviral and antibacterial agents, and the development of COX2 inhibitors.